Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACCENDRA HEALTH INC/VA/OMI · Entity 6858 | EVP, Chief Financial Officer | February 08, 2018 | February 12, 2018 |
| ACCURAY INCARAY · Entity 1170 | Director | October 05, 2026 | October 07, 2026 |
| BIOMARIN PHARMACEUTICAL INCBMRN · Entity 2404 | Director | December 31, 2025 | February 14, 2026 |
| Intersect ENT, Inc.XENT · Entity 127294 | EVP & Chief Financial Officer | May 13, 2022 | May 16, 2022 |
| Rockley Photonics Holdings LtdRKLY · Entity 122956 | President & CFO | October 21, 2022 | October 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACCENDRA HEALTH INC/VA/
Report date February 08, 2018 · Filed February 12, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 127,158 |
Reported balance
After 2018-02-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-08 · Grant · Acquired 22,013 · Balance 127,158 F1: Restricted stock with three year vesting date. F2: Balance includes employee stock purchase plan holdings and/or shares acquired through dividend reinvestment transactions not previously reflected in beneficial ownership total. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock with three year vesting date.
F2: Balance includes employee stock purchase plan holdings and/or shares acquired through dividend reinvestment transactions not previously reflected in beneficial ownership total.
ACCURAY INC
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 75,000 |
Reported balance
After 2026-10-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 75,000 · Balance 75,000 F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2: This represents a Restricted Stock Unit that vests in three equal annual installments beginning on the first anniversary of the grant date. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-10-05 | Direct | 75,000 |
Reported balance
After 2026-10-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-10-05 · Grant · Acquired 75,000 · Balance 75,000 F3: This represents a Non-Qualified Stock Option that will vest in three equal annual installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F2: This represents a Restricted Stock Unit that vests in three equal annual installments beginning on the first anniversary of the grant date.
F3: This represents a Non-Qualified Stock Option that will vest in three equal annual installments beginning on the first anniversary of the grant date.
BIOMARIN PHARMACEUTICAL INC
Report date December 31, 2025 · Filed February 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 126,926 |
Reported balance
After 2025-12-30 transaction · row 1
1 source rowRow 1 · 2025-12-30 · Gift · Disposed 500 · Balance 126,926 |
Intersect ENT, Inc.
Report date May 13, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-05-13 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-05-13 · Other · Disposed 57,230 · Balance 106,366 F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Row 2 · 2022-05-13 · Other · Disposed 65,759 · Balance 40,607 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Row 3 · 2022-05-13 · Other · Disposed 40,607 · Balance 0 F3: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. F4: Includes 4,400 shares at the children's trust. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.07 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-13 · Other · Disposed 34,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.60 · Expires 2029-11-26 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-13 · Other · Disposed 74,852 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F3: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].
F4: Includes 4,400 shares at the children's trust.
F5: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Rockley Photonics Holdings Ltd
Report date October 21, 2022 · Filed October 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 1,891,521 |
Reported balance
After 2022-10-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-10-21 · Grant · Acquired 1,891,521 · Balance 1,891,521 F1: The RSU will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.63 | Direct | 1,891,521 |
Reported balance
After 2022-10-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-21 · Grant · Acquired 1,891,521 · Balance 1,891,521 F2: The Stock Option will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The RSU will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control.
F2: The Stock Option will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 05, 2026 Filed Oct 7, 2026 20:10 UTC | ACCURAY INC ARAY · Entity 1170 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001214659-26-012649 · marketforms-74110.xml · derivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-10-05 F3 · derivative.exercise_date: This represents a Non-Qualified Stock Option that will vest in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| October 05, 2026 Filed Oct 7, 2026 20:10 UTC | ACCURAY INC ARAY · Entity 1170 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001214659-26-012649 · marketforms-74110.xml · derivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F1 · security: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: This represents a Restricted Stock Unit that vests in three equal annual installments beginning on the first anniversary of the grant date. F2 · derivative.expiration_date: This represents a Restricted Stock Unit that vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| December 30, 2025 Filed Feb 14, 2026 00:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-008241 · wk-form5_1771027202.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,926 Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:00 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 6,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-25-000076 · wk-form4_1747947594.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,426 F1 · price: Restricted stock units granted on May 20, 2025. Price not applicable. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 23:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 6,600 | $0.00 Strike: $63.10 | $0.00 |
DisclosureSEC source: 0001048477-24-000116 · wk-form4_1717543684.xml · derivative · entry 3 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,600 shares Expires 2024-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 23:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 5,451 | $76.41 | $416,510.91 |
DisclosureSEC source: 0001048477-24-000116 · wk-form4_1717543684.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,776 Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 23:28 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 6,600 | $63.10 | $416,460.00 |
DisclosureSEC source: 0001048477-24-000116 · wk-form4_1717543684.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,227 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2024 Filed May 23, 2024 21:34 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 7,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000108 · wk-form4_1716500073.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,627 F1 · price: Restricted stock units granted on May 21, 2024. Price not applicable. Read SEC document |
| January 08, 2024 Filed Jan 24, 2024 00:47 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001048477-24-000004 · wk-form4_1706057221.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,547 Read SEC document |
| May 23, 2023 Filed May 24, 2023 22:27 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031975 · doc4.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,547 F1 · price: Restricted stock units granted on May 23, 2023. Price not applicable. Read SEC document |
| May 12, 2023 Filed May 17, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to Buy Common Stock) · Derivative | 8,500 | $0.00 Strike: $67.81 | $0.00 |
DisclosureSEC source: 0001209191-23-030368 · doc4.xml · derivative · entry 3 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2023-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 12, 2023 Filed May 17, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Tax withholdingCommon Stock | 6,137 | $93.93 | $576,448.41 |
DisclosureSEC source: 0001209191-23-030368 · doc4.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,357 Read SEC document |
| May 12, 2023 Filed May 17, 2023 22:14 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 8,500 | $67.81 | $576,385.00 |
DisclosureSEC source: 0001209191-23-030368 · doc4.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 21, 2022 Filed Oct 21, 2022 17:43 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantStock Option (right to buy) · Derivative | 1,891,521 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001852117-22-000396 · wf-form4_166638860535626.xml · derivative · entry 2 MEIER RICHARD A · CIK 0001227305 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,891,521 Underlying: Ordinary Share · 1,891,521 shares Expires not disclosed F2 · derivative.exercise_date: The Stock Option will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. F2 · derivative.expiration_date: The Stock Option will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. Read SEC document |
| October 21, 2022 Filed Oct 21, 2022 17:43 UTC | Rockley Photonics Holdings Ltd RKLY · Entity 122956 | GrantRestricted Stock Unit · Derivative | 1,891,521 | $0.00 | $0.00 |
DisclosureSEC source: 0001852117-22-000396 · wf-form4_166638860535626.xml · derivative · entry 1 MEIER RICHARD A · CIK 0001227305 · President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,891,521 Underlying: Ordinary Share · 1,891,521 shares Expires not disclosed F1 · derivative.exercise_price: The RSU will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. F1 · derivative.exercise_date: The RSU will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. F1 · derivative.expiration_date: The RSU will vest over 4 years, with 25% vesting on the first anniversary of the date of grant, and the remaining 75% vesting in quarterly installments over the remaining 3 years, subject to continued service and acceleration upon a change in control. Read SEC document |
| May 24, 2022 Filed May 27, 2022 01:24 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,980 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-011798 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,994 F1 · price: Restricted stock units granted on May 24, 2022. Price not applicable. Read SEC document |
| May 13, 2022 Filed May 16, 2022 18:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | OtherStock Options (Right to buy) · Derivative | 74,852 | $28.25 Strike: $21.60 | $2,114,569.00 |
DisclosureSEC source: 0001562180-22-004076 · primarydocument.xml · derivative · entry 5 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 74,852 shares Expires 2029-11-26 F5 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| May 13, 2022 Filed May 16, 2022 18:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | OtherStock Options (Right to buy) · Derivative | 34,000 | $28.25 Strike: $23.07 | $960,500.00 |
DisclosureSEC source: 0001562180-22-004076 · primarydocument.xml · derivative · entry 4 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,000 shares Expires 2031-02-01 F5 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document |
| May 13, 2022 Filed May 16, 2022 18:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | OtherCommon Stock | 40,607 | $28.25 | $1,147,147.75 |
DisclosureSEC source: 0001562180-22-004076 · primarydocument.xml · nonDerivative · entry 3 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. F4 · shares: Includes 4,400 shares at the children's trust. F3 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. Read SEC document |
| May 13, 2022 Filed May 16, 2022 18:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | OtherCommon Stock | 65,759 | $28.25 | $1,857,691.75 |
DisclosureSEC source: 0001562180-22-004076 · primarydocument.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,607 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Read SEC document |
| May 13, 2022 Filed May 16, 2022 18:43 UTC | Intersect ENT, Inc. XENT · Entity 127294 | OtherCommon Stock | 57,230 | $28.25 | $1,616,747.50 |
DisclosureSEC source: 0001562180-22-004076 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,366 F1 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. F1 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to performance-based vesting conditions (each, an 'Issuer PSU') that was outstanding and became vested prior to or upon the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer PSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 8,500 | $0.00 Strike: $37.46 | $0.00 |
DisclosureSEC source: 0001567619-22-009496 · doc1.xml · derivative · entry 4 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2022-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 18 | $82.12 | $1,478.07 |
DisclosureSEC source: 0001567619-22-009496 · doc1.xml · nonDerivative · entry 3 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,014 Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 3,860 | $82.09 | $316,867.40 |
DisclosureSEC source: 0001567619-22-009496 · doc1.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,032 Read SEC document |
| May 02, 2022 Filed May 4, 2022 16:21 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 8,500 | $37.46 | $318,410.00 |
DisclosureSEC source: 0001567619-22-009496 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 21:06 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Tax withholdingCommon Stock | 2,329 | $27.31 | $63,596.61 |
DisclosureSEC source: 0001562180-22-001159 · primarydocument.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,596 F3 · shares: Shares tendered in payment of the tax withholding obligation in compliance and as required by the company's equity documents. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.20 to $27.55, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F5 · balance_after: Includes 122,989 restricted stock units, of which 57,230 are performance based. Read SEC document |
| February 01, 2022 Filed Feb 4, 2022 21:06 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 36,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001159 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,925 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the Vesting Commencement Date of February 1, 2022. F2 · balance_after: Includes 128,793 restricted stock units, of which 57,230 are performance based. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 18:07 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Tax withholdingCommon Stock | 6,346 | $26.94 | $170,953.62 |
DisclosureSEC source: 0001562180-21-007368 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,187 F1 · shares: Shares tendered in payment of the tax withholding obligation in compliance and as required by the company's equity documents. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.85 to $27.02, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 92,055 restricted stock units, of which 57,230 are performance based. Read SEC document |
| May 25, 2021 Filed May 27, 2021 23:29 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 5,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-011316 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,392 F1 · price: Restricted stock units granted on May 25, 2021. Price not applicable. Read SEC document |
| May 06, 2021 Filed May 7, 2021 23:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 15,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001567619-21-009351 · doc1.xml · derivative · entry 3 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2021-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| May 06, 2021 Filed May 7, 2021 23:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 5,068 | $78.38 | $397,245.04 |
DisclosureSEC source: 0001567619-21-009351 · doc1.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,272 F1 · price: The price in column 4 is the weighted average price. The price actually received ranged from $78.38 to $78.405. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. Read SEC document |
| May 06, 2021 Filed May 7, 2021 23:48 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionCommon Stock | 15,000 | $26.49 | $397,350.00 |
DisclosureSEC source: 0001567619-21-009351 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:35 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 34,000 | $0.00 Strike: $23.07 | $0.00 |
DisclosureSEC source: 0001562180-21-000884 · primarydocument.xml · derivative · entry 2 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2031-02-01 F3 · derivative.exercise_date: The vesting commencement date of the option is February 1, 2021. 1/8th of the shares subject to the option shall vest on August 1, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter over 42 months. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 20:35 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 17,411 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-000884 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,533 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the grant date. F2 · balance_after: Includes 109,468 restricted stock units, of which 57,230 are performance based. Read SEC document |
| November 27, 2020 Filed Dec 1, 2020 17:23 UTC | Intersect ENT, Inc. XENT · Entity 127294 | Tax withholdingCommon Stock | 6,349 | $20.00 | $127,002.86 |
DisclosureSEC source: 0001562180-20-006990 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,122 F1 · shares: Shares tendered in payment of the tax withholding obligation in compliance and as required by the company's equity documents. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.72 to $20.29, inclusive. The Reporting Person undertakes to provide, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F3 · balance_after: Includes 92,057 restricted stock units, of which 57,230 are performance based. Read SEC document |
| May 27, 2020 Filed May 29, 2020 22:07 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011364 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,340 F1 · price: Restricted stock units granted on May 27, 2020. Price not applicable. Read SEC document |
| March 17, 2020 Filed Mar 17, 2020 20:37 UTC | Intersect ENT, Inc. XENT · Entity 127294 | PurchaseCommon Stock | 5,000 | $7.80 | $38,997.00 |
DisclosureSEC source: 0001562180-20-002595 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,471 F1 · balance_after: Includes 109,471 restricted stock units, of which 57,230 are performance based. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 06:02 UTC | Intersect ENT, Inc. XENT · Entity 127294 | PurchaseCommon Stock | 2,500 | $13.75 | $34,375.00 |
DisclosureSEC source: 0001562180-20-002562 · primarydocument.xml · nonDerivative · entry 4 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,471 F1 · balance_after: Includes 109,471 restricted stock units, of which 57,230 are performance based. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 06:02 UTC | Intersect ENT, Inc. XENT · Entity 127294 | PurchaseCommon Stock | 2,500 | $13.50 | $33,750.00 |
DisclosureSEC source: 0001562180-20-002562 · primarydocument.xml · nonDerivative · entry 3 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,971 F1 · balance_after: Includes 109,471 restricted stock units, of which 57,230 are performance based. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 06:02 UTC | Intersect ENT, Inc. XENT · Entity 127294 | PurchaseCommon Stock | 2,500 | $12.75 | $31,875.00 |
DisclosureSEC source: 0001562180-20-002562 · primarydocument.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,471 F1 · balance_after: Includes 109,471 restricted stock units, of which 57,230 are performance based. Read SEC document |
| March 16, 2020 Filed Mar 17, 2020 06:02 UTC | Intersect ENT, Inc. XENT · Entity 127294 | PurchaseCommon Stock | 2,500 | $10.19 | $25,462.50 |
DisclosureSEC source: 0001562180-20-002562 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,971 F1 · balance_after: Includes 109,471 restricted stock units, of which 57,230 are performance based. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 13:44 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 74,852 | $0.00 Strike: $21.60 | $0.00 |
DisclosureSEC source: 0001562180-19-005773 · primarydocument.xml · derivative · entry 3 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,852 Underlying: Common Stock · 74,852 shares Expires 2029-11-26 F5 · derivative.exercise_date: The vesting commencement date of the option is November 26, 2019. 1/4th of the shares subject to the option shall vest on November 26, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter over 36 months. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 13:44 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 57,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-005773 · primarydocument.xml · nonDerivative · entry 2 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,471 F3 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units shall vest on the third anniversary from the date of grant provided that certain 30-day trailing average stock price (the "Average Closing Price") targets are achieved at any time during the three year period following the date of grant. 33 1/3%, 66 2/3% or 100% of the shares will vest if the Average Closing Price equals or exceeds specific stock price targets. F4 · balance_after: Restricted stock units, of which 57,230 are performance based. Read SEC document |
| November 26, 2019 Filed Nov 29, 2019 13:44 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 52,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-005773 · primarydocument.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,241 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest in three equal annual installments commencing one year after the grant date. F2 · balance_after: Restricted stock units. Read SEC document |
| June 11, 2019 Filed Jul 12, 2019 23:09 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GiftCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-014738 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,040 F1 · date: This transaction involved gifts of securities by the reporting person to irrevocable trusts for the benefit of the reporting person's children and for which the reporting person is not the trustee. The reporting person disclaims beneficial ownership of the shares held by such irrevocable trusts, and this report should not be deemed an admission that the reporting person is the beneficial owner of such shares. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 22:17 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | GrantCommon Stock | 4,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012978 · doc1.xml · nonDerivative · entry 1 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,040 F1 · price: Restricted stock units granted on June 4, 2019 . Price not applicable. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 12,000 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001567619-18-002765 · doc1.xml · derivative · entry 6 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | Exercise / conversionStock Option (Right to buy Common Stock) · Derivative | 3,000 | $0.00 Strike: $21.51 | $0.00 |
DisclosureSEC source: 0001567619-18-002765 · doc1.xml · derivative · entry 5 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 3,000 shares Expires 2020-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects the number of options outstanding after the transactions from this specific stock option grant. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 200 | $99.25 | $19,850.00 |
DisclosureSEC source: 0001567619-18-002765 · doc1.xml · nonDerivative · entry 4 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,610 Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 23:22 UTC | BIOMARIN PHARMACEUTICAL INC BMRN · Entity 2404 | SaleCommon Stock | 2,800 | $99.24 | $277,872.00 |
DisclosureSEC source: 0001567619-18-002765 · doc1.xml · nonDerivative · entry 3 MEIER RICHARD A · CIK 0001227305 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,810 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.